Spectrum Management Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Spectrum Management Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$162K	Hold	560	–	–	0.04%	106
2022 Q2	$158K	Hold	560	–	–	0.04%	108
2022 Q1	$146K	Hold	560	–	–	0.02%	119
2021 Q4	$123K	Sell	560 -16	-3%	-$3.11K	0.02%	132
2021 Q3	$104K	Buy	576 +16	+3%	+$3.12K	0.02%	143
2021 Q2	$113K	Hold	560	–	–	0.02%	125
2021 Q1	$120K	Hold	560	–	–	0.02%	124
2020 Q4	$132K	Hold	560	–	–	0.03%	117
2020 Q3	$152K	Hold	560	–	–	0.04%	112
2020 Q2	$163K	Hold	560	–	–	0.04%	111
2020 Q1	$133K	Buy	+560	New	+$128K	0.04%	99
2019 Q4	–	Sell	-560	Closed	-$95K	–	251
2019 Q3	$95K	Hold	560	–	–	0.03%	119
2019 Q2	$103K	Hold	560	–	–	0.03%	128
2019 Q1	$103K	Hold	560	–	–	0.03%	107
2018 Q4	$93K	Buy	+560	New	+$97K	0.03%	102

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Spectrum Management Group's VRTX Position: Q3 2022 in Review

Spectrum Management Group held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2022 at 560 shares worth $162K. The position accounts for 0.04% of the portfolio, ranked #106.

Spectrum Management Group first reported a position in VRTX in Q4 2018 and has held it in 15 quarters since. The position peaked at $163K in Q2 2020. 1,124 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.

Spectrum Management Group held 560 shares of Vertex Pharmaceuticals worth $162K as of Q3 2022.
Spectrum Management Group left its Vertex Pharmaceuticals share count unchanged in Q3 2022.
Vertex Pharmaceuticals made up 0.04% of Spectrum Management Group's portfolio in Q3 2022, its #106 holding.
Spectrum Management Group first reported a position in Vertex Pharmaceuticals in Q4 2018 and has held it in 15 quarters since.
Spectrum Management Group's Vertex Pharmaceuticals position peaked at $163K in Q2 2020.
1,124 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.

Based on Spectrum Management Group's 13F filing for Q3 2022, filed 1 Nov 2022.